Illumina (ILMN) Expected to Post Quarterly Earnings on Thursday

Key Points

• Illumina is expected to report Q3 2026 results after market close on October 29. Analysts forecast earnings of $1.36 per share on $1.15 billion in revenue, while the company’s full-year EPS guidance is $5.30–$5.40.
• In its latest quarter, Illumina beat consensus estimates with $1.31 EPS versus $1.23 expected and $1.16 billion in revenue. Revenue increased 9.4% year over year.
• Analyst sentiment remains mixed despite significant stock gains. Illumina has a consensus “Hold” rating and a $231.88 price target, while insiders sold about 2.06 million shares worth $436.5 million over the past three months.

Illumina (NASDAQ:ILMN - Get Free Report) is expected to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect Illumina to announce earnings of $1.36 per share and revenue of $1.15 billion for the quarter. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. During the same quarter in the prior year, the business posted $1.19 EPS. The firm's revenue was up 9.4% compared to the same quarter last year. On average, analysts expect Illumina to post $5.36 EPS for the current fiscal year and $6.12 EPS for the next fiscal year.

Illumina Price Performance

Shares of NASDAQ ILMN opened at $282.86 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm's 50-day simple moving average is $239.24 and its 200 day simple moving average is $189.54. The stock has a market cap of $42.71 billion, a price-to-earnings ratio of 52.03, a PEG ratio of 3.79 and a beta of 1.41. Illumina has a fifty-two week low of $94.00 and a fifty-two week high of $309.35.

Insider Buying and Selling

In related news, SVP Christensen Wedel sold 1,033 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total value of $197,840.16. Following the sale, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. This represents a 6.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the business's stock in a transaction on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the completion of the sale, the director directly owned 770,350 shares in the company, valued at $168,244,440. This trade represents a 13.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 2,061,850 shares of company stock worth $436,479,102. Insiders own 2.90% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. Weiss Ratings restated a "hold (c)" rating on shares of Illumina in a report on Monday, August 31st. Barclays upped their price target on shares of Illumina from $160.00 to $200.00 and gave the company an "underweight" rating in a research note on Wednesday, October 7th. Stifel Nicolaus increased their target price on Illumina from $155.00 to $225.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Piper Sandler raised their price target on Illumina from $225.00 to $305.00 and gave the stock an "overweight" rating in a report on Monday, September 28th. Finally, Sanford C. Bernstein restated a "market perform" rating and issued a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Illumina presently has an average rating of "Hold" and a consensus target price of $231.88.

About Illumina

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company's offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.